A study of CTX-1302 for the treatment of Attention Deficit – Hyperactivity Disorder (ADHD).
Phase of Trial: Phase I
Latest Information Update: 16 Jul 2018
Price : $35 *
At a glance
- Drugs Dexamfetamine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions
- 16 Jul 2018 Status changed from planning to completed.
- 11 Aug 2017 New trial record
- 08 Aug 2017 Accordign to a Cingulate Therapeutics media release, the company plans to initiate this study in 2018.